Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply. JAMA oncology Sledge, G. W., Frenzel, M. n. 2020

View details for DOI 10.1001/jamaoncol.2020.1518

View details for PubMedID 32463426